Nobuhiro Hata
Overview
Explore the profile of Nobuhiro Hata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1029
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inoue H, Kuroda J, Fujioka Y, Hata N, Mizoguchi M, Yoshii D, et al.
Surg Neurol Int
. 2024 Dec;
15:417.
PMID: 39640311
Background: Combination therapy with BRAF and MEK inhibitor holds promise for treating gliomas harboring the V600E mutation; however, the development of acquired resistance remains a challenge. Case Description: We describe...
2.
Higa N, Akahane T, Kirishima M, Yonezawa H, Makino R, Uchida H, et al.
Pathol Res Pract
. 2024 Oct;
263:155598.
PMID: 39357189
Previously, we constructed a DNA-based next-generation sequencing (NGS) panel for an integrated diagnosis of gliomas according to the 2021 World Health Organization classification system. The aim of the current study...
3.
Otsuji R, Hata N, Yamamoto H, Kuga D, Hatae R, Sangatsuda Y, et al.
Neurooncol Adv
. 2024 Jul;
6(1):vdae069.
PMID: 39022644
Background: Homozygous deletion of the tumor suppression genes cyclin-dependent kinase inhibitor 2A/B () is a strong adverse prognostic factor in IDH-mutant gliomas, particularly astrocytoma. However, the impact of hemizygous deletion...
4.
Hata N, Fujioka Y, Otsuji R, Kuga D, Hatae R, Sangatsuda Y, et al.
Neuropathology
. 2024 Mar;
44(5):344-350.
PMID: 38477051
Since the World Health Organization (WHO) 2016 revision, the number of molecular markers required for diffuse gliomas has increased, placing a burden on clinical practice. We have established an in-house,...
5.
Otsuji R, Fujioka Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473369
Glioma is one of the most common primary central nervous system (CNS) tumors, and its molecular diagnosis is crucial. However, surgical resection or biopsy is risky when the tumor is...
6.
Ito Y, Hata N, Maesawa S, Tanei T, Ishizaki T, Mutoh M, et al.
Epilepsia Open
. 2024 Jan;
9(2):592-601.
PMID: 38173171
Objective: Patients with epilepsy have high risk of experiencing uncommon causes of death. This study aimed to evaluate patients who underwent unusual deaths related to epilepsy and identify factors that...
7.
Sugita K, Anan M, Matsuta H, Shimomura T, Fudaba H, Hata N, et al.
Front Neurol
. 2023 Oct;
14:1173285.
PMID: 37900594
The neural mechanisms underlying gross and fine motor dysfunction after subarachnoid hemorrhage (SAH) remain unknown. The γ-aminobutyric acid (GABA) deficit hypothesis proposes that reduced neuronal GABA concentrations and the subsequent...
8.
Nagashima Y, Nishimura Y, Kanemura T, Hata N, Satake K, Akahori S, et al.
Neurol Med Chir (Tokyo)
. 2023 Oct;
63(12):548-554.
PMID: 37853614
There is a lack of agreement on whether minimally invasive lateral lumbar intervertebral fusion (LLIF) is a suitable treatment option for vertebral fragility fractures (VFFs). Hence, we sought to evaluate...
9.
Shirozu N, Ohgidani M, Hata N, Tanaka S, Inamine S, Sagata N, et al.
Sci Rep
. 2023 Sep;
13(1):14842.
PMID: 37684266
Angiogenic factors associated with Moyamoya disease (MMD) are overexpressed in M2 polarized microglia in ischemic stroke, suggesting that microglia may be involved in the pathophysiology of MMD; however, existing approaches...
10.
Otsuji R, Hata N, Funakoshi Y, Kuga D, Togao O, Hatae R, et al.
Neurol Med Chir (Tokyo)
. 2023 Jul;
63(8):364-374.
PMID: 37423755
We aimed to retrospectively determine the resection rate of fluid-attenuated inversion recovery (FLAIR) lesions to evaluate the clinical effects of supramaximal resection (SMR) on the survival of patients with glioblastoma...